What Counts as an FDA-Approved Peptide
An FDA-approved peptide is a peptide-based drug that has completed the full regulatory approval process — preclinical testing, Phase I through Phase III clinical trials, a New Drug Application (NDA) or Biologics License Application (BLA), FDA review, and post-market surveillance. These drugs meet pharmaceutical-grade manufacturing standards (cGMP) and have established safety and efficacy data from controlled human trials.
This distinction matters because the peptide research community uses many compounds that are not FDA-approved — BPC-157, TB-500, CJC-1295, Ipamorelin, and others. Understanding which peptides have full regulatory backing versus which are research compounds helps you assess the level of evidence, quality control, and legal status behind each one.
Master List of FDA-Approved Peptide Drugs
GLP-1 Receptor Agonists (Metabolic / Weight Loss)
The GLP-1 class is the largest and most commercially significant group of peptide drugs on the market. These mimic glucagon-like peptide-1, a gut-derived incretin hormone that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central satiety pathways.
| Generic Name | Brand Name(s) | FDA Approval Year | Approved Indication(s) | Manufacturer |
|---|---|---|---|---|
| Semaglutide (injection) | Ozempic | 2017 | Type 2 diabetes | Novo Nordisk |
| Semaglutide (injection) | Wegovy | 2021 | Chronic weight management, CV risk reduction | Novo Nordisk |
| Semaglutide (oral) | Rybelsus | 2019 | Type 2 diabetes | Novo Nordisk |
| Tirzepatide | Mounjaro | 2022 | Type 2 diabetes | Eli Lilly |
| Tirzepatide | Zepbound | 2023 | Chronic weight management | Eli Lilly |
| Liraglutide | Victoza | 2010 | Type 2 diabetes | Novo Nordisk |
| Liraglutide | Saxenda | 2014 | Chronic weight management | Novo Nordisk |
| Exenatide | Byetta | 2005 | Type 2 diabetes | AstraZeneca |
| Exenatide ER | Bydureon BCise | 2012 | Type 2 diabetes | AstraZeneca |
| Dulaglutide | Trulicity | 2014 | Type 2 diabetes, CV risk reduction | Eli Lilly |
| Lixisenatide | Adlyxin | 2016 | Type 2 diabetes | Sanofi |
Key pharmacology: All GLP-1 agonists are resistant to DPP-4 degradation (the enzyme that breaks down native GLP-1 in minutes). Semaglutide achieves its ~7-day half-life through albumin binding and C-18 fatty acid acylation. Tirzepatide is unique as a dual GIP/GLP-1 agonist — it activates both incretin receptors, which may explain its superior efficacy in head-to-head trials versus semaglutide (SURMOUNT vs STEP trial data).
Growth Hormone-Related Peptides
| Generic Name | Brand Name(s) | FDA Approval Year | Approved Indication(s) | Manufacturer |
|---|---|---|---|---|
| Tesamorelin | Egrifta SV | 2010 | HIV-associated lipodystrophy (excess abdominal fat) | Theratechnologies |
| Sermorelin | Geref (discontinued) | 1997 | Diagnostic agent for GH deficiency in children | EMD Serono |
| Somatropin (recombinant HGH) | Genotropin, Humatrope, Norditropin, others | 1985+ | GH deficiency (pediatric and adult), Turner syndrome, short bowel, others | Multiple |
| Somapacitan | Sogroya | 2020 | Adult GH deficiency | Novo Nordisk |
| Lonapegsomatropin | Skytrofa | 2021 | Pediatric GH deficiency | Ascendis Pharma |
| Mecasermin (IGF-1) | Increlex | 2005 | Severe primary IGF-1 deficiency | Ipsen |
Key notes: Tesamorelin is the only FDA-approved GHRH analog currently marketed. It stimulates pituitary GH release (like CJC-1295 and Sermorelin) but is approved only for HIV lipodystrophy, not general anti-aging or body composition use. Sermorelin (Geref) received FDA approval as a diagnostic agent but was voluntarily withdrawn from the market by its manufacturer — it remains legally available through compounding pharmacies due to its prior approval status, which gives it stronger legal standing than never-approved peptides.
Melanocortin Peptides
| Generic Name | Brand Name(s) | FDA Approval Year | Approved Indication(s) | Manufacturer |
|---|---|---|---|---|
| Bremelanotide | Vyleesi | 2019 | Hypoactive sexual desire disorder (premenopausal women) | Palatin Technologies |
| Setmelanotide | Imcivree | 2020 | Obesity due to POMC, PCSK1, or LEPR deficiency | Rhythm Pharmaceuticals |
Key pharmacology: Bremelanotide is a synthetic melanocortin-4 receptor (MC4R) agonist derived from Melanotan II. Unlike Melanotan II (a research chemical), bremelanotide is administered as a subcutaneous injection on-demand (at least 45 minutes before anticipated sexual activity) rather than continuously. It does not cause the tanning effect associated with Melanotan II because its MC1R activity is lower.
Reproductive and Hormonal Peptides
| Generic Name | Brand Name(s) | FDA Approval Year | Approved Indication(s) | Manufacturer |
|---|---|---|---|---|
| Oxytocin | Pitocin | 1980 | Labor induction, postpartum hemorrhage | Multiple |
| Gonadorelin | Factrel | 1982 | Diagnostic agent for gonadotropin function | Multiple |
| Leuprolide | Lupron, Lupron Depot | 1985 | Prostate cancer, endometriosis, precocious puberty, uterine fibroids | AbbVie |
| Goserelin | Zoladex | 1989 | Prostate cancer, breast cancer, endometriosis | AstraZeneca |
| Nafarelin | Synarel | 1990 | Endometriosis, precocious puberty | Pfizer |
| Cetrorelix | Cetrotide | 2000 | Premature LH surge prevention in IVF | EMD Serono |
| Ganirelix | Ganirelix Acetate | 2000 | Premature LH surge prevention in IVF | Organon |
| Degarelix | Firmagon | 2008 | Advanced prostate cancer | Ferring |
| Elagolix | Orilissa | 2018 | Endometriosis-associated pain | AbbVie |
| Relugolix | Orgovyx | 2020 | Advanced prostate cancer | Myovant Sciences |
| Linzagolix | Yselty | 2024 | Uterine fibroids, endometriosis | Theramex |
Key pharmacology: GnRH agonists (leuprolide, goserelin, nafarelin) initially stimulate then suppress gonadotropin release through pituitary desensitization — the “flare then suppress” mechanism. GnRH antagonists (cetrorelix, ganirelix, degarelix) provide immediate suppression without the initial flare, making them preferable when rapid hormone suppression is needed. Oral GnRH antagonists (elagolix, relugolix, linzagolix) represent the newest generation — they allow dose-dependent partial suppression rather than complete shutdown.
ACTH and Corticotropin Peptides
| Generic Name | Brand Name(s) | FDA Approval Year | Approved Indication(s) | Manufacturer |
|---|---|---|---|---|
| Corticotropin (ACTH) | H.P. Acthar Gel | 1952 | Infantile spasms, nephrotic syndrome, MS exacerbations, rheumatic disorders | Mallinckrodt |
| Cosyntropin | Cortrosyn | 1970 | Diagnostic test for adrenal function | Amphastar |
Other Notable FDA-Approved Peptides
| Generic Name | Brand Name(s) | FDA Approval Year | Approved Indication(s) | Manufacturer |
|---|---|---|---|---|
| Calcitonin (salmon) | Miacalcin, Fortical | 1995 | Postmenopausal osteoporosis | Multiple |
| Octreotide | Sandostatin | 1988 | Acromegaly, carcinoid tumors, VIPomas | Novartis |
| Lanreotide | Somatuline Depot | 2007 | Acromegaly, neuroendocrine tumors | Ipsen |
| Pasireotide | Signifor | 2012 | Cushing’s disease, acromegaly | Recordati |
| Teriparatide (PTH 1-34) | Forteo | 2002 | Osteoporosis | Eli Lilly |
| Abaloparatide | Tymlos | 2017 | Osteoporosis in postmenopausal women | Radius Health |
| Plecanatide | Trulance | 2017 | Chronic idiopathic constipation, IBS-C | Salix |
| Linaclotide | Linzess | 2012 | IBS-C, chronic idiopathic constipation | AbbVie/Ironwood |
| Ziconotide | Prialt | 2004 | Severe chronic pain (intrathecal) | Jazz Pharmaceuticals |
| Nesiritide | Natrecor | 2001 | Acute decompensated heart failure | Janssen |
| Difelikefalin | Korsuva | 2021 | CKD-associated pruritus (itching in dialysis patients) | Vifor Pharma |
Research Peptides NOT FDA-Approved
The following peptides are widely used in the research community but have no FDA approval, no completed Phase III trials, and no NDA on file. They exist in the regulatory gray area as research chemicals.
| Peptide | Status | Why Not FDA-Approved | Compounding Status |
|---|---|---|---|
| BPC-157 | Research chemical | No IND filed, no human clinical trials completed, synthetic origin (not endogenous) | Category 2 — banned from compounding (Sept 2023) |
| TB-500 (Thymosin Beta-4) | Research chemical | No completed clinical trials for common use cases | Not available through compounding |
| CJC-1295 (with/without DAC) | Research chemical | Modified GHRH analog, no NDA filed | Available at some compounding pharmacies (Category 2 risk) |
| Ipamorelin | Research chemical | GHRP with Phase II data but no Phase III completion | Available at some compounding pharmacies |
| MK-677 (Ibutamoren) | Research chemical | Extensive Phase II data but development discontinued by Merck | Not typically compounded (oral compound) |
| GHRP-2 | Research chemical | No NDA filed despite clinical studies | Available at some compounding pharmacies |
| GHRP-6 | Research chemical | No NDA filed | Available at some compounding pharmacies |
| AOD-9604 | Research chemical | Phase II obesity trial showed no efficacy (Metabolic Pharmaceuticals, 2007) | Not typically compounded |
| GHK-Cu | Research chemical / cosmetic ingredient | Used in cosmetics; injectable form has no clinical trial program | Available at some compounding pharmacies |
| Selank | Research chemical | Approved in Russia (not FDA); no US clinical trials | Not typically compounded |
| Semax | Research chemical | Approved in Russia (not FDA); no US clinical trials | Not typically compounded |
| Epitalon (Epithalon) | Research chemical | Limited human data; telomerase activation mechanism | Not typically compounded |
| MOTS-c | Research chemical | Mitochondrial peptide; very early research stage | Not typically compounded |
| DSIP | Research chemical | Delta sleep-inducing peptide; limited reproducible data | Not typically compounded |
| KPV | Research chemical | Alpha-MSH fragment; anti-inflammatory; very limited human data | Not typically compounded |
| LL-37 | Research chemical | Human cathelicidin antimicrobial peptide; no drug development program | Not typically compounded |
| Retatrutide | Investigational (Phase III) | Eli Lilly triple agonist in active clinical development; potential approval 2026-2027 | Not compounded (investigational) |
Why so few peptides get FDA-approved: The FDA approval process costs $1-2 billion and takes 10-15 years. Most research peptides cannot be patented (they are naturally occurring sequences or well-known modifications), which means no pharmaceutical company can recoup the investment through exclusivity. This is the fundamental economic barrier — not safety concerns. The compounds with FDA approval are overwhelmingly those with patent protection (novel modifications like semaglutide’s C-18 fatty acid chain) or orphan drug designations.
503A vs 503B Compounding Pharmacies
Compounding pharmacies operate under two different regulatory frameworks, and understanding the difference matters for peptide access.
503A Pharmacies (Traditional Compounding)
- Regulation: State boards of pharmacy + FDA oversight
- Requirement: Must compound based on individual patient prescriptions
- Scale: Small-batch, patient-specific preparations
- Quality standard: USP <795> and <797> (sterile compounding)
- GMP required: No (but must follow USP standards)
- Distribution: Limited to the prescribing practitioner’s patients; some interstate distribution
503A pharmacies are traditional compounding pharmacies that mix custom preparations for individual patients. Your local compounding pharmacy is likely a 503A facility.
503B Outsourcing Facilities
- Regulation: Direct FDA oversight (registered with FDA)
- Requirement: Can compound without individual prescriptions
- Scale: Larger batches, “office use” distribution to clinics
- Quality standard: cGMP (current Good Manufacturing Practice)
- GMP required: Yes
- Distribution: National distribution to healthcare facilities
503B facilities were created by the Drug Quality and Security Act of 2013 (following the 2012 New England Compounding Center meningitis outbreak that killed 76 people). They operate under stricter manufacturing standards and can produce larger quantities.
What This Means for Peptide Access
| Factor | 503A | 503B |
|---|---|---|
| Peptide availability | More peptides available (less FDA scrutiny) | Fewer peptides, but higher quality assurance |
| Prescription required | Yes (patient-specific) | Not always (office use stock) |
| Quality testing | Varies by pharmacy | Mandatory potency and sterility testing |
| FDA inspection | Periodic | Regular, announced and unannounced |
| Cost | Often lower | Often higher (GMP overhead) |
| Risk | Higher variability between pharmacies | Lower — more standardized |
For peptides like CJC-1295 and Ipamorelin that are still available through compounding, 503B facilities generally provide more reliable potency and sterility testing. The price premium (typically 20-40% more) buys manufacturing quality assurance.
The FDA Peptide Crackdown (2023-2026)
Timeline of Key Actions
September 2023 — BPC-157 Category 2 Listing. The FDA determined that BPC-157 lacks sufficient safety data for compounding. This was the first major action specifically targeting a research peptide popular in the wellness community. BPC-157 was banned from all 503A and 503B compounding pharmacies effective immediately.
Late 2023 — Semaglutide Shortage List Changes. As Novo Nordisk resolved manufacturing shortages, the FDA began removing semaglutide dosage forms from the drug shortage list. Under federal law, compounding pharmacies can only compound copies of commercially available drugs when those drugs are on the shortage list. As semaglutide came off the list, compounding authorization narrowed.
2024 — Compounding Industry Legal Challenges. The Outsourcing Facilities Association (OFA) and other industry groups filed lawsuits challenging the FDA’s authority to restrict compounding of GLP-1 agonists. Courts issued mixed rulings — some temporary restraining orders allowed compounding to continue while cases were decided.
2024-2025 — Enforcement Actions. The FDA issued warning letters and took enforcement action against compounding pharmacies making unapproved therapeutic claims about peptide products. Several pharmacies were ordered to cease production of specific peptides.
2025-2026 — Ongoing Litigation and Regulation. The legal battle over compounded semaglutide and tirzepatide remains active. The FDA’s Category 2 review process continues evaluating additional peptides. The regulatory environment remains volatile — what is available through compounding in early 2026 may change within months.
Why the FDA Is Tightening Peptide Regulations
The FDA’s stated concerns center on three issues:
-
Patient safety. Compounded peptides do not undergo the same potency, purity, and sterility testing as FDA-approved drugs. The FDA has documented cases of under-potent and contaminated compounded products.
-
Unapproved therapeutic claims. Many clinics and pharmacies market compounded peptides for conditions (anti-aging, fat loss, muscle building) that have no FDA-approved indication and limited clinical evidence.
-
Market protection. Critics argue the FDA’s actions also protect the commercial interests of pharmaceutical companies whose patent-protected products face price competition from compounded versions. The semaglutide case is the clearest example — compounded semaglutide cost $100-300/month versus $1,000+/month for Ozempic or Wegovy.
The Pipeline: Peptide Drugs in Development
Several peptide-class drugs are in late-stage clinical trials with potential near-term FDA approval.
| Drug | Type | Developer | Phase | Target Indication | Potential Approval |
|---|---|---|---|---|---|
| Retatrutide | GIP/GLP-1/Glucagon triple agonist | Eli Lilly | Phase III | Obesity, T2D | 2026-2027 |
| Survodutide | GLP-1/Glucagon dual agonist | Boehringer Ingelheim | Phase III | MASH (fatty liver), obesity | 2026-2027 |
| Orforglipron | Non-peptide oral GLP-1 agonist | Eli Lilly | Phase III | T2D, obesity | 2026-2027 |
| Pemvidutide | GLP-1/Glucagon dual agonist | Altimmune | Phase II | MASH, obesity | 2027+ |
| CagriSema | Semaglutide + cagrilintide | Novo Nordisk | Phase III | Obesity | 2026-2027 |
| Ecnoglutide | Long-acting GLP-1 agonist | CSPC Pharmaceutical | Phase III | T2D, obesity | 2026+ |
What to watch: The obesity and metabolic pipeline is dominated by peptide-class drugs. Retatrutide is the most anticipated — its Phase II results showed up to 24.2% body weight reduction at 48 weeks, which would make it the most effective weight loss drug ever approved if Phase III confirms the data. The GLP-1 class is expanding rapidly, with dual and triple agonists representing the next generation.
How to Verify FDA Approval Status
Before relying on any claim about a peptide’s FDA status (including this guide), verify it directly:
- FDA Drugs@FDA database — drugs.fda.gov — searchable database of all FDA-approved drugs with approval letters, labels, and review documents
- FDA Orange Book — lists approved drugs with patent and exclusivity information
- ClinicalTrials.gov — search for active or completed clinical trials for any peptide
- FDA Drug Shortages database — current status of drug shortages affecting compounding availability
- FDA Category 2 list — substances banned from compounding under 503A/503B
These databases are updated in real time and supersede any third-party source.
Related Resources
- Peptide Legality & FDA Status Guide — comprehensive legal framework for all peptides
- Semaglutide Protocol — dosing guide for the most prescribed peptide drug
- Tirzepatide Protocol — dual agonist protocol and comparison to semaglutide
- Tesamorelin Protocol — the only FDA-approved GHRH analog
- Sermorelin Protocol — prior FDA approval gives it unique legal standing
- Reconstitution Calculator — dosing math for research-grade peptides
Frequently Asked Questions
How many FDA-approved peptide drugs are there? +
There are over 80 FDA-approved peptide drugs as of 2026. These range from insulin analogs and GLP-1 agonists to oxytocin, ACTH, and gonadotropin-releasing hormone analogs. The most well-known recent approvals include semaglutide (Ozempic/Wegovy, 2017/2021), tirzepatide (Mounjaro/Zepbound, 2022/2023), and bremelanotide (Vyleesi, 2019).
Is BPC-157 FDA-approved? +
No. BPC-157 has never been submitted for FDA approval and has no Investigational New Drug (IND) application on file. In September 2023, the FDA placed BPC-157 on its Category 2 list, which prohibits compounding pharmacies from producing it. BPC-157 remains available only as a research chemical labeled 'not for human consumption.'
What is the difference between FDA-approved and compounded peptides? +
FDA-approved peptides have completed the full regulatory process — preclinical studies, Phase I-III clinical trials, manufacturing review, and post-market surveillance. They are manufactured under strict GMP standards. Compounded peptides are mixed by compounding pharmacies (503A or 503B facilities) and are not individually FDA-approved, though they use bulk drug ingredients. Compounded versions are typically cheaper but have less regulatory oversight.
Can I get FDA-approved peptides without a prescription? +
No. All FDA-approved peptide drugs are prescription-only medications in the United States. You need a valid prescription from a licensed healthcare provider. Telehealth platforms and anti-aging clinics can prescribe many of these medications after a consultation. Over-the-counter peptide products (like collagen peptides or cosmetic copper peptides) are classified as supplements or cosmetics, not drugs.
Are any new peptide drugs expected to be FDA-approved soon? +
Retatrutide (Eli Lilly's triple agonist — GIP/GLP-1/glucagon) is in Phase III trials with potential approval in 2026-2027. Survodutide (Boehringer Ingelheim's dual agonist) is in late-stage trials for MASH and obesity. Orforglipron (Eli Lilly) could become the first oral non-peptide GLP-1 agonist. The obesity and metabolic drug pipeline is the most active area for new peptide-class approvals.